dr. Dave Sprengers

Medicine & Life Sciences

1. Hepatocellular Carcinoma 100%
2. Liver Transplantation 71%
3. T-Lymphocytes 57%
4. Neoplasms 52%
5. Liver Neoplasms 48%
6. Immunosuppression 44%
7. Liver 40%
8. Sorafenib 35%
9. Recurrence 29%
10. Immunosuppressive Agents 29%
11. Survival 28%
12. thymoglobulin 27%
13. Circulating Tumor DNA 27%
14. Klatskin Tumor 27%
15. Cancer-Associated Fibroblasts 26%
16. CTLA-4 Antigen 26%
17. Organoids 24%
18. Regulatory T-Lymphocytes 24%
19. Interleukin-15 24%
20. Circulating Neoplastic Cells 23%
21. Tumor Necrosis Factor Receptors 21%
22. Testicular Neoplasms 21%
23. Radiosurgery 20%
24. Immunity 20%
25. Neoplasm Antigens 20%
26. Feasibility Studies 19%
27. Tumor Microenvironment 19%
28. Therapeutics 19%
29. Netherlands 18%
30. Pancreatic Neoplasms 17%
31. Transplant Recipients 17%
32. Glucocorticoids 17%
33. Cytokines 16%
34. Radiotherapy 15%
35. Tissue Donors 14%
36. Antibodies 13%
37. Cholangiocarcinoma 13%
38. Safety 12%
39. Immunotherapy 12%
40. Drug Therapy 11%
41. Antigens 11%
42. Antibody Formation 10%
43. Mutation 10%
44. Graft Survival 9%
45. Incidence 9%
46. Pharmaceutical Preparations 8%
47. Transplants 8%
48. Natural Killer Cells 8%
49. Ligation 8%
50. Tumor-Infiltrating Lymphocytes 8%